Skip to content

Dermacyte Amniotic Wound Care Matrix

Harnessing the power of amniotic tissue to advance wound healing

The Dermacyte Difference: Real-World Evidence in Wound Care1

Dermacyte Matrix represents an innovative approach in advanced wound care.

DERMACYTE MATRIX is a commercially available extracellular tissue product and is intended for use as a protective covering for partial and full thickness wounds and surgical sites.

Dermacyte® Matrix

Dermacyte® Amniotic Wound Care Matrix (Dermacyte Matrix) is a human amniotic membrane allograft with a preserved epithelial basement membrane and compact fibroblast layer.

Based on proprietary advancements in amniotic tissue processing, Dermacyte Matrix is created from amniotic tissue that undergoes rigorous screening and is produced under the highest quality standards.

Dermacyte Matrix excels in 

icon for convenience


Ease of use across various clinical settings.

icon for pain reduction

Clinically Tested:

Peer reviewed literature in multiple applications.1

icon for Natural Antimicrobial Protection


Wound bed protection from the external environment.

icon for Storage Efficiency

Storage Efficiency:

Stable and uncomplicated storage

Application and Usage of Dermacyte Matrix

Dermacyte Matrix provides a protective barrier to cover wounds and soft tissue.

Dermacyte Matrix is a versatile covering that may be applied to various hard-to-heal wounds, including:

Download Brochure

Diabetic ulcers
Venous ulcers
Pressure ulcers
Deep dermal ulcers exposing underlying tendons, muscles or bones
photos of doctors operating and a family spending time together

Dermacyte Matrix Specifications

Product SKU Identifier Matrix Size (LxW, cm)
AM-D10012 MT10012 1×2
AM-D10022 MT10022 2×2
AM-D10023 MT10023 2×3
AM-D10024 MT10024 2×4
AM-D10044 MT10044 4×4
AM-D10046 MT10046 4×6
AM-D10048 MT10048 4×8
AM-D10912 MT10912 9×12
Photo of professionals chatting while walking

and Support for Dermacyte Matrix

Merakris offers a comprehensive reimbursement support for providers using Dermacyte Matrix. To get your copy, complete this form.


Dermacyte Matrix is regulated by the U.S. Food and Drug Administration (FDA) as a minimally manipulated human allograft tissue under its Human Cells, Tissues, and Tissue-Based Products (HCT/P) guidelines, subject to Section 361 of the Public Health Service Act and 21 CFR 1271.

Regulatory Compliance

Merakris Therapeutics is committed to being a best in class organization in the development and commercialization of healthcare technologies in order to provide customers the highest quality products that offer consistent safety and performance.

FDA registered and audited source facilities

Manufactured in accordance with 21 CFR 1271



  1. Ditmars FS, Kay KE, Broderick TC, Fagg WS. Use of amniotic membrane in hard-to-heal wounds: a multicentre retrospective study. J Wound Care. 2024 Mar 1;33(Sup3):S44-S50. doi: 10.12968/jowc.2024.33.Sup3.S44. PMID: 38457299.

Partner with us for advanced wound care

Interested in learning more about using or distributing Dermacyte Matrix?